



US00RE42096E

(19) **United States**
(12) **Reissued Patent**
Burnside et al.

(10) **Patent Number:** **US RE42,096 E**
(45) **Date of Reissued Patent:** **Feb. 1, 2011**

- (54) **ORAL PULSED DOSE DRUG DELIVERY SYSTEM**
- (75) Inventors: **Beth A. Burnside**, Bethesda, MD (US); **Xiaodi Guo**, Apex, NC (US); **Kimberly Fiske**, Downingtown, PA (US); **Richard A. Couch**, Bryn Mawr, PA (US); **Rong-Kun Chang**, Rockville, MD (US); **Donald J. Treacy**, Woodbine, MD (US); **Charlotte M. McGuinness**, Bethesda, MD (US); **Edward M. Rudnic**, North Potomac, MD (US)
- (73) Assignee: **Shire LLC, USA**
- (21) Appl. No.: **11/091,011**
- (22) Filed: **Mar. 24, 2005**

| | | | | |
|--------------|------|---------|------------------|---------|
| 5,260,069 | A | 11/1993 | Chen | |
| 5,275,819 | A | 1/1994 | Amer et al. | |
| 5,308,348 | A | 5/1994 | Balaban et al. | |
| 5,328,697 | A * | 7/1994 | Raman et al. | 424/477 |
| 5,364,620 | A | 11/1994 | Geoghegan et al. | |
| 5,378,474 | A | 1/1995 | Morella et al. | |
| 5,395,628 | A | 3/1995 | Noda et al. | |
| 5,407,686 | A | 4/1995 | Patel et al. | |
| 5,422,121 | A | 6/1995 | Lehmann et al. | |
| 5,474,786 | A | 12/1995 | Kotwal et al. | |
| 5,496,561 | A | 3/1996 | Okada et al. | |
| 5,616,345 | A | 4/1997 | Geoghegan et al. | |
| 5,773,031 | A * | 6/1998 | Shah et al. | 424/497 |
| 5,837,284 | A * | 11/1998 | Mehta et al. | 424/459 |
| 5,840,329 | A | 11/1998 | Bai | |
| 6,005,027 | A * | 12/1999 | Guillet et al. | 523/209 |
| 6,475,493 | B1 | 11/2002 | Mulye | |
| 6,605,300 | B1 * | 8/2003 | Burnside et al. | 424/452 |
| 6,749,867 | B2 | 6/2004 | Robinson et al. | |
| 6,764,696 | B2 | 7/2004 | Pather et al. | |
| 2004/0059002 | A1 | 3/2004 | Couch et al. | |

Related U.S. Patent Documents

- Reissue of:
- (64) Patent No.: **6,322,819**
 - Issued: **Nov. 27, 2001**
 - Appl. No.: **09/176,542**
 - Filed: **Oct. 21, 1998**

- (51) **Int. Cl.**
A61K 9/16 (2006.01)
- (52) **U.S. Cl.** **424/494; 424/472; 424/480; 424/489; 424/490; 424/494; 424/471; 424/497; 424/461; 424/462; 424/470; 424/458; 424/459; 424/460; 424/468; 424/482**
- (58) **Field of Classification Search** **424/451, 424/452, 464, 465, 474, 481, 489, 490, 494, 424/472**

See application file for complete search history.

FOREIGN PATENT DOCUMENTS

| | | |
|----|---------------|---------|
| AU | 109438 | 1/1940 |
| EP | 640 337 | 3/1995 |
| JP | 59-082311 | 5/1984 |
| JP | 03-148215 | 6/1991 |
| JP | 07-061922 | 3/1995 |
| JP | 09-249557 | 9/1997 |
| JP | 09-267035 | 10/1997 |
| JP | 10-081634 | 3/1998 |
| WO | WO87/00044 | 1/1987 |
| WO | WO90/09168 | 8/1990 |
| WO | 97/03673 | 2/1997 |
| WO | 98/14168 | 4/1998 |
| WO | WO 99/03471 A | 1/1999 |
| WO | WO 00/25752 A | 5/2000 |
| WO | WO 00/35450 A | 6/2000 |

OTHER PUBLICATIONS

US 6,034,101, 3/2000, Gupta et al. (withdrawn)
 Conte, et al., "Press-coated tablets for time-programmed release of drugs," *Biomaterials*, 14(13):1017-1023 (1993).
 Gazzaniga, et al., "Time-dependent oral delivery systems for colon targeting," *S.T.P. Pharma Sciences*, 5(1):83-88 (1995).

(Continued)

Primary Examiner—S. Tran
 (74) *Attorney, Agent, or Firm*—McDermott Will & Emery LLP

(57) **ABSTRACT**

A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| | | | | |
|-----------|-----|---------|------------------|---------|
| 2,099,402 | A | 11/1937 | Keller | |
| 2,738,303 | A | 3/1956 | Blythe | |
| 2,881,113 | A * | 4/1959 | Max | |
| 3,048,526 | A | 8/1962 | Boswell | |
| 3,066,075 | A * | 11/1962 | Deutsch | 424/459 |
| 3,365,365 | A | 1/1968 | Butler et al. | |
| 3,979,349 | A | 9/1976 | Fink | |
| 4,049,791 | A | 9/1977 | Cohen | |
| 4,723,958 | A | 2/1988 | Pope et al. | |
| 4,728,512 | A | 3/1988 | Mehta et al. | |
| 4,794,001 | A | 12/1988 | Mehta et al. | |
| 4,871,549 | A | 10/1989 | Ueda et al. | |
| 4,891,230 | A | 1/1990 | Geoghegan et al. | |
| 4,894,240 | A | 1/1990 | Geoghegan et al. | |
| 4,902,516 | A | 2/1990 | Korsatko et al. | |
| 4,917,899 | A | 4/1990 | Geoghegan et al. | |
| 5,002,776 | A | 3/1991 | Geoghegan et al. | |
| 5,011,692 | A | 4/1991 | Fujioka et al. | |
| 5,011,694 | A | 4/1991 | Nuernberg et al. | |
| 5,051,262 | A | 9/1991 | Panoz et al. | |
| 5,093,200 | A | 3/1992 | Watanabe et al. | |
| 5,137,733 | A | 8/1992 | Noda et al. | |
| 5,156,850 | A | 10/1992 | Wong et al. | |
| 5,202,159 | A | 4/1993 | Chen et al. | |
| 5,226,902 | A | 7/1993 | Boe et al. | |



OTHER PUBLICATIONS

- Gazzaniga, et al., "Oral Chronotropic Drug Delivery Systems: Achievement of Time and/or Site Specificity," *Eur. J. Pharm. Biopharma* 40(3):246–250 (1994).
- Pozzi, et al, The Time Clock system: a new oral dosage form for fast and complete release of drug after a predetermined lag time., *Journal of Controlled Release*, 31:99–108 (1994).
- Walia et al., "Preliminary Evaluation of an Aqueous Wax Emulsion for Controlled-Release Coating," *Pharmaceutical Development and Technology*, 3(1):103–113 (1998).
- Wilding, et al., "Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation," *Pharmaceutical Research*, 9(5):654–657 (1992).
- Xin Xu and Ping I. Lee, "Programmable Drug Delivery from an Erodible Association Polymer System," *Pharmaceutical Research*, 10(8):1144–1152 (1993).
- Barr Laboratories Inc.'s Objections and Responses to Shire Laboratories Inc.'s Second Set of Interrogatories (Nos. 8–11), dated Feb. 18, 2004.
- Barr Laboratories' Objections and Responses to Plaintiff Shire Laboratories Inc.'s Fourth Set of Interrogatories (Nos. 15–16), dated Jul. 9, 2004.
- Barr Laboratories' Supplemental Objections and Responses to Plaintiff Shire Laboratories Inc.'s Third Set of Interrogatories (Nos. 12–14 Redacted), dated Aug. 27, 2004.
- Barr Laboratories' Objections and Responses to Plaintiff Shire Laboratories Inc.'s Fifth Set of Interrogatories (No. 17), dated Sep. 3, 2004.
- Barr Laboratories' Memorandum In Support of its Motion to Amend its Pleadings and exhibits thereto, dated Sep. 10, 2004.
- Deposition transcript of Honorable Gerald J. Mossinghoff and exhibits thereto, dated Jun. 8, 2005.
- Impax Laboratories Inc.'s First Amended Answer and Affirmative Defenses, dated May 2, 2005.
- Barr Laboratories' Memorandum in Support of its Motion to Compel Production, dated Sep. 13, 2004.
- Complaint for Declaratory Judgment, *Impax Laboratories Inc. v. Shire International Laboratories, Inc.* (Civ. Action No. 05772) and Exhibits attached thereto, dated Nov. 9, 2005.
- Angrist et al., Early Pharmacokinetics and Clinical Effects of Oral D-Amphetamine in Normal Subjects, *Biol. Psychiatry* 1987, 22: 1357–1368.
- Brauer et al., Acute Tolerance to Subjective but not Cardiovascular Effects of d-Amphetamine in normal, Healthy Men, *Journal of Clinical Psychopharmacology*, 1996; 16(1):73–76.
- Brown et al., Behavior and Motor Activity Response in Hyperactive Children and Plasma Amphetamine Levels Following a Sustained Release Preparation, *Journal of the American Academy of Child Psychiatry*, 19:225–239, 1980.
- Brown et al., Plasma Levels of d-Amphetamine in Hyperactive Children, *Psychopharmacology* 62, 133–140, 1979.
- R. Bianchini & C. Vecchio, Oral Controlled Release Optimization of Pellets Prepared by Extrusion-Spheronization Processing, *IL Farmaco* 44(6), 645–654, 1989.
- Burns et al., A study of Enteric-coated Liquid-filled Hard Gelatin Capsules with Biphasic Release Characteristics, *International Journal of Pharmaceutics* 110 (1994) 291–296.
- Bodmeier et al., The Influence of Buffer Species and Strength on Diltiazem HCl Release from Beads Coated with
- Cody et al., Amphetamine Enantiomer Excretion Profile Following Administration of Adderall, *Journal of Analytical Toxicology*, vol. 2, Oct. 2003, 485–492.
- Rong-Kun Chang, A Comparison of Rheological and Enteric Properties among Organic Solutions, Ammonium Salt Aqueous Solutions, and Latex Systems of Some Enteric Polymers, *Pharmaceutical Technology*, Oct. 1990.
- Chang et al., Preparation and Evaluation of Shellac Pseudolatex as an Aqueous Enteric Coating Systems for Pellets, *International Journal of Pharmaceutics*, 60 (1990) 171–173, 1990.
- Daynes, Treatment of Nocturnal Enuresis with Enteric-Coated Amphetamine, *The Practitioner*, No. 1037, vol. 173, Nov. 1954.
- Garnett et al., Pharmacokinetic Evaluation of Twice-Daily Extended-Release Carbamazepine (CBZ) and Four-Times-Daily Immediate-Release CBZ in Patients with Epilepsy, *Epilepsia* 39(3):274–279, 1998.
- Goodhart et al., An Evaluation of Aqueous Film-Forming Dispersions for Controlled Release, *Pharmaceutical Technology*, Apr. 1984.
- Greenhill et al., A Pharmacokinetic/Pharmacodynamic Study Comparing a Single Morning Dose of Adderall to Twice-Daily Dosing in Children with ADHD. *J. Am. Acad. Adolesc. Psychiatry*, 42:10, Oct. 2003.
- Husson et al., Influence of Size Polydispersity on Drug Release from Coated Pellets, *International Journal of Pharmaceutics*, 86 (1992) 113–121, 1992.
- Ishibashi et al., Design and Evaluation of a New Capsule-type Dosage Form for Colon-Targeted Delivery of Drugs, *International Journal of Pharmaceutics* 168, (1998) 31–40, 1998.
- Kao et al., Lag Time Method to Delay Drug Release to Various Sites in the Gastrointestinal Tract, *Journal of Controlled Release* 44(1997) 263–270.
- Kiriyama et al., The Bioavailability of Oral Dosage Forms of a New HIV-1 Protease Inhibitor, KNI-272, in Beagle Dogs, *Biopharmaceutics & Drug Disposition*, vol. 17 125–234 (1996).
- Hans-Martin Klein & Rolf W. Gunther, Double Contrast Small Bowel Follow-Through with an Acid-Resistant Effervescent Agent, *Investigative Radiology* vol. 28, Jul. 1993.
- Krowczynski & Brozyna, Extended-Release Dosage Forms, pp. 123–131 (1987).
- Hall HS and Pondell RE, Controlled Release Technologies: Method, Theory, and Applications, pp. 133–154 (Agis F. Kydonieus ed. 1980).
- Treatise on Controlled Drug Delivery, pp. 185–199 (Agis Kydonieus ed. 1992).
- Leopold & Eikeler, Eudragit E as Coating Material for the pH-Controlled Drug Release in the Topical Treatment of Inflammatory Bowel Disease (IBD), *Journal of Drug Targeting*, 1998, vol. 6, No. 2, pp. 85–94.
- Klaus Lehmann, Coating of Multiparticulates Using Polymeric Solutions, *Multiparticulate Oral Drug Delivery* (Swarbrick and Sellassie ed., 1994).
- Lin & Cheng, In-vitro Dissolution Behaviour of Spansule-type Micropellets Prepared by Pan Coating Method, *Pharm. Ind.* 51 No. 5 (1989).
- C. Lin et al., Bioavailability of d-pseudoephedrine and Aza-

- C. Lin et al., Comparative Bioavailability of d-pseudoephedrine from a Conventional d-pseudoephedrine Sulfate Tablet and from a Repeat Action Tablet, *J Int Med Res* (1982) 10, 126–128.
- Rosen et al., Absorption and Excretion of Radioactively Tagged Dextroamphetamine Sulfate from a Sustained-Release Preparation, *Jama*, vol. 194, No. 11, Dec. 13, 1965, 145–147.
- Liu et al., Comparative Release of Phenylprepanolamine ECI from Long-Acting Appetite Suppressant Product: Acutrim vs. Dexatrim, *Drug Development and Industrial Pharmacy*, 10(10), 1639–1661 (1984).
- Marcotte et al., Kinetics of Protein Diffusion from a Poly(D, L-Lactide) Reservoir System, *Journal of Pharmaceutical Sciences* vol. 79, No. 5, May 1990.
- Mathir et al., In vitro characterization of a controlled-release chlorpheniramine maleate delivery system prepared by the air-suspension technique, *J. Microencapsulation*, vol. 14, No. 6, 743–751 (1997).
- Mehta et al., Evaluation of Fluid-bed Processes for Enteric Coating Systems, *Pharmaceutical Technology*, Apr. 1986.
- McGough et al., Pharmacokinetics of SL1381 (Adderall XR), an Extended-Release Formulation of Adderall, *Journal of the American Academy of Child & Adolescent Psychiatry*, vol. 42, No. 6, Jun. 2003.
- Harris et al., Aqueous Polymeric Coating for Modified-Release Pellets, *Aqueous Polymeric Coating for Pharmaceutical Dosage Forms* (McGinity ed., 1989).
- Kennerly S. Patrick & John S. Markowitz, Pharmacology of Methylphenidate, Amphetamine Enantiomers and Pemoline in Attention-Deficit Hyperactivity Disorder, *Human Psychopharmacology*, vol. 12, 527–546 (1997).
- Pelham et al., A Comparison of Morning-Only and Morning/Late Afternoon Adderall to Morning-Only, Twice-Daily, and Three Times-Daily Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder, *Pediatrics*, vol. 104, No. 6, Dec. 1999.
- American Chemical Society, *Polymer Preprints*, pp. 633–634, vol. 34, No. 1, Mar. 1993.
- Rambali, et al., Using experimental design to optimize the process parameters in fluidized bed granulation on a semi-full scale, *International Journal of Pharmaceutics* 220 (2001) 149–160.
- Charles S.L. Chlao and Joseph R. Robinson, *Sustained-Release Drug Delivery Systems*, Remington: The Science and Practice of Pharmacy, Tenth Edition (1995) 1660–1675.
- Rosen, et al., Absorption and Excretion of Radioactively Tagged Dextroamphetamine Sulfate From a Sustained-Release Preparation, *Journal of the American Medical Association*, Dec. 13, 1965, vol. 194, No. 11, 1203–1205.
- Scheiffle, et al., Studies Comparing Kollicoat MAE 30 D with Commercial Cellulose Derivatives for Enteric Coating on Caffeine Cores, *Drug Development and Industrial Pharmacy*, 24(9), 807–818 (1998), 807–818.
- Serajuddin, et al., Selection of Solid Dosage Form Composition through Drug-Excipient Compatibility Testing, *Journal of Pharmaceutical Sciences* vol. 88, No. 7, Jul. 1999, 696–704.
- Sheen et al., Aqueous Film Coating Studies of Sustained Release Nicotinic Acid Pellets: An In-Vitro Evaluation, Slattum, et al., Comparison of Methods for the Assessment of Central Nervous System Stimulant Response after Dextroamphetamine Administration to Healthy Male Volunteers, *J. Clin Pharmacol* 1996; 36: 1039–1050.
- Sriamornsak, et al., Development of sustained release theophylline pellets coated with calcium pectinate, *Journal of Controlled Release* 47 (1997) 221–232.
- Edward Stempel, *Prolonged Drug Action*, HUSA's Pharmaceutical Dispensing, Sixth Edition, 1966, 464, 481–485.
- Stevens, et al., Controlled, Multidose, Pharmacokinetic Evaluation of Two Extended-Release Carbamazepine Formulations (Carbatrol and Tegretol-XR), *Journal of Pharmaceutical Sciences* vol. 87, No. 12, Dec. 1998, 1531–1534.
- J. Sjogren, Controlled release oral formulation technology, *Rate Control in Drug Therapy*, (1985) 38–47.
- Agyilrah GA and Bauker SB, *Polymers for Enteric Coating Applications*, *Polymers for Controlled Drug Delivery* (Peter J. Tarcha ed. 1991) 39–66.
- Leon Lachman, Herbert A. Lieberman, Joseph L. Kanig, *The Theory and Practice of Industrial Pharmacy*, Second Edition (1976) 371–373.
- Remington's *Pharmaceutical Sciences*, Fifteenth Edition (1975) 1624–1625.
- Tulloch, et al., SL1381 (Adderall XR), a Two-component, Extended-Release Formulation of Mixed Amphetamine Salts: Bioavailability of Three Test Formulations and Comparison of Fasted, Fed, and Sprinkled Administration, *PHARMACOTHERAPY* vol. 22, No. 11. (2002), 1405–1415.
- Vasilevska, et al., Preparation and Dissolution Characteristics of Controlled Release Diltiazem Pellets, *Drug Development and Industrial Pharmacy*, 18(15), 1649–1661 (1992).
- Watano, et al., Evaluation of Aqueous Enteric Coated Granules Prepared by Moisture Control Method in Tumbling Fluidized Bed Process, *Chem. Pharm. Bull.* 42(3) 663–667 (1994).
- Wesdyk, et al., Factors affecting differences in film thickness of beads coated in fluidized bed units, *International Journal of Pharmaceutics*, 93 101–109, (1993).
- Wouessidjewe, Aqueous polymethacrylate Dispersions as Coating Materials for Sustained and Enteric Release Systems, *S.T.P. Pharma Sciences* 7(6) 469–475 (1997).
- Ansel, et al., *Rate Controlled Dosage Forms and Drug Delivery Systems*, *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 6th Ed. (1995), 213–222.
- Bauer, et al., Cellulose Acetate Phthalate (CAP) and Trimellitate (CAT), *Coated Pharmaceutical Dosage Forms* (1998), 102–104.
- Chan, *New Polymers for Controlled Release Products*, *Controlled Release Dosage Forms Proceedings of the International Symposium held on 29th to 31st of Jan. 1987* (The Bombay College of Pharmacy 1988) 59–67.
- Chan, *Materials Used for Effective Sustained-Release Products*, *Proceedings of the International Symposium held on 29th to 31st of Jan. 1987* (The Bombay College of Pharmacy 1988), 69–84.
- Moller, *Dissolution Testing of Delayed Release Preparations*, *Proceedings of the International Symposium held on 29th to 31st of Jan. 1987* (The Bombay College of Pharmacy 1988), 85–11.
- Fukumori, *Coating of Multiparticulates Using Polymeric*

- Handbook of Pharmaceutical Excipients: Ethylcellulose, Polymethacrylates, (4th ed. (2003), 237–240, 462–468.
- Handbook of Pharmaceutical Excipients: Polymethacrylates, (2nd ed. 1994), 361–366.
- Hawley's Condensed Chemical Dictionary 13th Ed. 1997, 584, 981.
- Jarowski, The Pharmaceutical Pilot Plant, Pharmaceutical Dosage Forms: Tablets, vol. 3, 2nd Ed. (1990), 303–367.
- McGraw-Hill Dictionary of Scientific and Technical Terms, 5th Ed. (1994), 97, 972.
- Physicians' Desk Reference: Adderall, 51st Ed. (1997).
- Physicians' Desk Reference: Adderall, 56th Ed. (2002).
- Physicians' Desk Reference: Dexedrine 56th Ed. (2002).
- Physicians' Desk Reference: Ritalin, 56th Ed. (2002).
- Remington: The Science and Practice of Pharmacy, Basic Pharmacokinetics, 16th Ed. (1980), 693.
- Remington: The Science and Practice of Pharmacy, Elutriation, 20th Ed. (2000), 690.
- Rong-Kun Chang and Joseph R. Robinson, Sustained Drug Release from Tablets and Particles Through Coating, Pharmaceutical Dosage Forms: Tablets (Marcel Dekker, Inc. 1990), 199–302.
- Shargel; Pharmacokinetics of Oral Absorption, Applied Biopharmaceutics & Pharmacokinetics. 5th Ed. (2005), 164–166.
- Spowls' American Pharmacy: An Introduction to Pharmaceutical Techniques and Dosage Forms, 7th Ed. (1974), 387–388.
- The Merck Index: Amphetamine, 12th Ed., 620.
- The Merck Index: Amphetamine, 13th Ed., (2001), 97, 1089.
- The United States Pharmacopeia 23, National Formulary 18 (1995) pp. 1791–1799.
- The United States Pharmacopeia 26, National Formulary 21 (2003) pp. 2157–2165.
- The United States Pharmacopeia 27, National Formulary 22 (2004) pp. 2302–2312.
- Answering Expert Report of Dr. Alexander Klibanov, Apr. 25, 2005.
- Answering Expert Report of Robert Langer, Apr. 25, 2005.
- Expert Report of Dr. Joseph R. Robinson and exhibits thereto, Feb. 28, 2005.
- Expert Report of the Honorable Gerald J. Mossinghoff and exhibits thereto, Mar. 16, 2005.
- Impax Laboratories, Inc.'s Memorandum in Support of the Motion to Amend its Answer dated Feb. 25, 2005 and exhibits thereto.
- Impax Laboratories, Inc.'s Reply Memorandum in Support of the Motion to Amend its Answer dated Mar. 18, 2005 and exhibit thereto.
- Impax Laboratories, Inc.'s First Supplemental Responses to Shire Laboratories Inc.'s First Set of Interrogatories (Nos. 11–12).
- Opening Expert Report of Dr. Michael Mayersohn and exhibits thereto, Mar. 12, 2005.
- Opening Expert Report of Dr. Walter Chambliss and exhibits thereto, Mar. 15, 2005.
- Couch Deposition Transcript, Sep. 8, 2004.
- Fiske Deposition Transcript, Sep. 17, 2004.
- Guo Deposition Transcript, Jul. 26, 2004.
- McGuinness Deposition Transcript, Aug. 6, 2004.
- Rudnic Deposition Transcript, Jul. 28, 2004.
- Chang Deposition Transcript, Sep. 8, 2004.
- Harrington Deposition Transcript, Jul. 27, 2005.
- Schaffer Deposition Transcript, Aug. 17, 2005.
- Burnside Deposition Transcript, Feb. 3, 2005.
- Guo Deposition Transcript, Jan. 24, 2005.
- Chang Deposition Transcript, Jan. 20, 2005.
- Adderall XR Package Inset, Sep. (2004).
- Freedom of Information Request Results for—Dexadrine (SmithKline Beecham): May 20, 1976 Disclosable Approval Information.
- Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations (1997).
- Guidance for Industry: Food-Effext Bioavailability and Fed Bioequivalence Studies (2002).
- Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms (1997).
- Holt, Bioequivalence Studies of Ketoprofen: Product formulation, Pharmacokinetics, Deconvolution, and In Vitro-In Vivo correlations, Thesis submitted to Oregon State University, Aug. (1997).
- Teva Notice letter: Feb. 21, 2005.
- Teva Notice letter: Jun. 1, 2005.
- PDR Drug Information for Ritalin LA Capsules, Apr. (2004).
- Prescribing Information: Dexedrine, brand of dextroamphetamine sulfate (2001).
- Shire Laboartories Inc.'s Opposition to Barr Laboratories' Motion to Amend Its Answers and Counterclaims, Sep. 15, 2004.
- Notice of Allowance U.S. Appl. No. 11/091,010 filed dated Dec. 22, 2008.
- Interview Summary U.S. Appl. No. 11/091,010 filed date Dec. 22, 2008.
- Wigal, et al., Evaluation of Individual Subjects in the Analog Classroom Setting; II. Effects of dose of amphetamine (Adderall), Psychopharmacology Bulletin, vol. 34, No. 4, pp. 833–838, 1998.
- Judgment and Order of Permanent Injunction in Shire LLC v. Teva Pharmaceutical Industries Ltd. in the United States District Court for the Eastern District of Pennsylvania, Civil Action No. 06–952–SD, Mar. 6, 2008.
- Notice of Allowance in U.S. Appl. No. 11/091,011 dated Jul. 20, 2007.
- Petition to Withdraw Application from Issue Pursuant to 37 CFR 1.313(c)(2) dated Oct. 16, 2007.
- Transcrip of Richard A. Couch 30(b)(6) Deposition in Shire LLC vs. Sandoz Inc. in the United States District Court for the District of Colorado, Dec. 14, 2007.
- Transcript of Beth A. Burnside Deposition in Shire LLC vs. Sandoz Inc. in the United States District Court for the District of Colorado, Case No. 07–CV–001197–EWN–CBS, Nov. 30, 2007.
- Transcript of Kimberly Fiske Farrand Deposition in Shire, LLC v. Sandoz, Inc. in the United States District Court of Colorado, Dec. 4, 2007.
- Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire LLC's Interrogatories (No. 1–9), in the United States District Court for the District of Colorado, Case No. 07–CV–001197–EWN–CBS, Jun. 18, 2007.
- Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire LLC's Second Set of Interrogatories (No. 10–19),

Defendant Sandoz, Inc.'s Answers and Objections to Plaintiff Shire LLC's Second Set of Interrogatories (No. 20–25) and Supplement to Answers to Interrogatories 8 and 9, in the United States District Court for the District of Colorado, Case No. 07–CV–001197–EWN–CBS, Dec. 10, 2007.

Expert Report of Arthur J. Steiner in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, case No. 1:07–cv–00718, Dec. 20, 2007.

Supplemental Expert Report of Harry G. Brittain, PhD, FRSC in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07–cv–00718, Feb. 15, 2008.

Ozturk et al., "Kinetics of Release from Enteric-Coated Tablets," *Pharmaceutical Research* 1988;5:550–565.

Ghebre-Sellassie et al., "Evaluation of acrylic-based modified-release film coatings," *International Journal of Pharmaceutics*, 1987;37:211–218.

Order and Memorandum Denying Colony's Motion for Partial Summary Judgment of Noninfringement of the '819 and '300 Patents in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. CCB–07–718, Jan. 2, 2008.

Plaintiff Shire LLC's Responses to Interrogatories No. 1–13 in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07–cv–00718–CCB, Jun. 6, 2007.

Transcript of Richard A. Couch Deposition in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07–cv–00718–CCB, Nov. 15, 2007.

Transcript of Beth A. Burnside Deposition in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07–cv–00718–CCB, Nov. 9, 2007.

Transcript of richard Rong–Kun Chang in Shire LLC v. Colony Pharmaceuticals, Inc., in the United States District Court for the District of Maryland, Case No. 1:07–cv–00718–CCB, Nov. 20, 2007.

Second Amended Complaint for Patent Infringement and Declaratory Relief in Shire Laboratories, Inc. v. Andrx Pharmaceuticals, LLC, in the United States District Court for the Southern District of Florida, Miami Division, Case No. 07–22201–CIV–Cooke/Brown, Nov. 15, 2007.

Answer and Counterclaims in Shire Laboratories, Inc. v. Andrx, LLC, in the United States District Court for the Southern District of Florida, Miami Division, Case No. 07–22201–CIV–Cooke/Brown, Aug. 31, 2007.

Plaintiffs Shire Laboratories, Inc.'s and Shire LLC's Reply to Defendant Andrx Pharmaceuticals, LLC's Counterclaims, in the United States District Court for the Southern District of Florida, Miami Division, Case No. 07–22201–CIV–Cooke/Brown, Sep. 24, 2007.

Judgment and Order of Permanent Injunction in Shire Laboratories, Inc. v. Andrx Pharmaceuticals, LLC, in the United States District Court for the Southern District of Florida, Miami Division, Case No. 07–22201–CIV–Cooke/Brown, Nov. 19, 2007.

* cited by examiner

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.